Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESA - Esmolol versus Sufentanil on the quality of recovery after laparoscopic cholecystectomy
2024-520282-31-00Phase 4Authorised
- Sponsor
- CHU de Limoges
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esmolol and sufentanil in postoperative pain and Delayed postoperative recovery (DPR) (2 arms), sponsored by CHU de Limoges. Primary endpoint: Quality of postoperative recovery (fQoR-15 score) on postoperative day 1. Planned start May 2025; status: authorised.
02
Drugs
esmololsufentanil
03
Conditions
postoperative painDelayed postoperative recovery (DPR)
Beyond the preview
Go deeper on 2024-520282-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520282-31-00.